BIOLINERX     Print Page  Close Window

SEC filings
BIOLINERX LTD. filed this Form 6-K on 04/05/2017
Entire Document


Exhibit 99.1



For Immediate Release


BioLineRx Closes $28.75 Million Underwritten Public Offering

of its American Depositary Shares


Tel Aviv, Israel - April 5, 2017 - BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical stage biopharmaceutical development company focused on oncology and immunology, today announced that it has closed its previously announced underwritten public offering of approximately 33.8 million American Depositary Shares (“ADSs”), each representing one (1) of its ordinary shares, at a public offering price of $0.85 per ADS, for gross proceeds of $28.75 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioLineRx. All of the ADSs in the offering were sold by BioLineRx. The amount of ADSs sold includes an additional approximately 4.4 million ADSs purchased by the underwriters pursuant to the option granted to them by BioLineRx. BioLineRx anticipates using the net proceeds from the offering to fund a number of clinical trials, including for BL-8040 and AGI-134, and for working capital and general corporate purposes.


JMP Securities acted as sole book-running manager for the offering. H.C. Wainwright & Co., LLC acted as lead manager. Maxim Group acted as co-manager.


The ADSs were issued pursuant to a shelf registration statement that was previously filed with, and declared effective by, the Securities and Exchange Commission (“SEC”). A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website located at


This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of a prospectus supplement and accompanying prospectus forming a part of the effective registration statement, copies of which may be obtained, when available, from JMP Securities LLC, 600 Montgomery Street, Suite 100, San Francisco, California 94111, Attention: Prospectus Department, or by telephone: (415) 835-8985.


About BioLineRx


BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and immunology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.